Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03170323
Other study ID # GGH2016430H
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date July 1, 2018
Est. completion date December 31, 2020

Study information

Verified date February 2019
Source Guangdong General Hospital
Contact xinling Liang, M.D.,PH.D
Phone 13808819770
Email xinlingliang_ggh@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Idiopathic membranous nephropathy (IMN) remains a common cause of the nephrotic syndrome in adults. There are few randomized clinical trials regarding the therapeutic effect of mycophenolate mofetil in patients with Idiopathic membranous nephropathy. This study aims to evaluate whether treatment with mycophenolate mofetil is non-inferior to cyclosporins in inducing long-term remission (complete or partial) of proteinuria in patients with idiopathic membranous nephropathy.


Description:

Idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults. In recent year, IMN remains one of the most common glomerular diseases. Long-term remission and stable renal function can prevent idiopathic membranous nephropathy from progressing to end-stage renal disease. Cyclosporine and cyclophosphamide are recommended to be first-line treatment regimen. Corticosteroid is the basic combined drug in the treatment of idiopathic membranous nephropathy. Mycophenolate mofetil is a recently developed immunosuppressive agent with fewer renal toxicity than cyclosporin.Besides, high dose prednisone may be effective for patients in Asia according to literatures from Asia. In our study, patients with idiopathic membranous nephropathy would be treated with mycophenolate mofetil and high dose prednisone,whose outcome will be compared with cyclosporin and low dose prednisone. We aims to evaluate whether treatment with mycophenolate mofetil is non-inferior to cyclosporins in inducing long-term remission of proteinuria in patients with idiopathic membranous nephropathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 128
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 1.Patients who provided informed consent

- 2.Patients who are diagnosed as membranous nephropathy by renal biopsy,and other secondary factors are excluded

- 3.18 years of age or older, male or female

- 4.24 hours urine protein or spot urine protein/creatinine ratio > 8.0 g/day at least for twice confirmed

- 5.The patients that satisfy more than three of following items are included even if proteinuria is less than 8 grams per day:

1. estimated glomerular filtration rate(eGFR) < 60 ml/min/1.73m2

2. Hypertension (BP above 140/90millimetre of mercury or BP above 120/80millimetre of mercury in patients taking anti-hypertensive agents)

3. 24 hours urine protein or spot urine protein/creatinine ratio > 5.0 g/day

4. Serum albumin (g/dL) < 3.0

Exclusion Criteria:

- 1.Severe infective disease

- 2.Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently.

- 3.Clinical history of treatment with other immunosuppressive medication

- 4.Probability of pregnancy, breast feeding woman

- 5.Uncontrolled hypertension (more than 160/100 millimetre of mercury )

- 6.estimated glomerular filtration rate(eGFR)<30 ml/min/1.73m2?

- 7.Abnormal liver function test (more than 3 times above compared with normal value)

- 8.Absolute neutrophil count <1,500/mm3 or leukocyte <2,500/mm3 or platelets <100,000/mm3

- 9.Secondary membranous nephropathy

- 10.Expected life expectancy is less than 1 year

- 11.The researchers evaluated that the patient's compliance was not appropriate for the trial

- 12.Previous or present history of cancer and have risk of recurrence or metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mycophenolate Mofetil
steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
Cyclosporins
steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d

Locations

Country Name City State
China Guangdong General Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangdong General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Remission Urinary protein excretion<0.3 g/d (uPCR<300 mg/g or <30 mg/mmol), confirmed by two values at least 1 week apart, accompanied by a normal serum albumin concentration, and a normal serum creatinine. after treatment for 1 year.
Primary Partial Remission Urinary protein excretion <3.5 g/d (uPCR <3500 mg/g or <350 mg/mmol) and a 50% or greater reduction from peak values;confirmed by two values at least 1 week apart, accompanied by an improvement or normalization of the serum albumin concentration and stable serum creatinine. after treatment for 1 year.
Secondary estimated Glomerular Filtration Rate time to a 50% reduction in baseline estimated Glomerular Filtration Rate (according to CKD-EPI) after treatment for 1 year
Secondary serum creatinine time to doubling of baseline creatinine after treatment for 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06245707 - the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy N/A
Recruiting NCT03864250 - Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy N/A
Completed NCT01180036 - MEmbranous Nephropathy Trial Of Rituximab Phase 2/Phase 3
Completed NCT01845688 - Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy N/A
Withdrawn NCT01093781 - Aliskiren in Patients With Idiopathic Membranous Nephropathy N/A
Completed NCT00362531 - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Phase 2/Phase 3
Recruiting NCT05839314 - Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy Phase 4
Completed NCT00302523 - Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy N/A
Terminated NCT03466801 - The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. N/A
Terminated NCT03475602 - Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy
Not yet recruiting NCT05850845 - Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Not yet recruiting NCT05667896 - Prognostic Model of GC/TAC in the Treatment of MN
Not yet recruiting NCT05667922 - Prognostic Model of TAC in the Treatment of MN
Not yet recruiting NCT05667909 - Prognostic Model of Rituximab in the Treatment of MN
Not yet recruiting NCT05667883 - Prognostic Model of GC/CTX in the Treatment of MN
Recruiting NCT02173106 - A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy Phase 2
Completed NCT01161459 - Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid N/A
Recruiting NCT03549663 - Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) N/A
Not yet recruiting NCT05845762 - Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
Completed NCT00694863 - Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy Phase 2